Glymphatic system dysfunction in neurodegenerative diseases

Center for Translational Neuromedicine

Glymphatic system dysfunction in neurodegenerative diseases

Research output: Contribution to journal › Review › Research › peer-review

Standard

Glymphatic system dysfunction in neurodegenerative diseases. / Beschorner, Natalie; Nedergaard, Maiken.

In: Current Opinion in Neurology, Vol. 37, No. 2, 2024, p. 182-188.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Beschorner, N & Nedergaard, M 2024, 'Glymphatic system dysfunction in neurodegenerative diseases', Current Opinion in Neurology, vol. 37, no. 2, pp. 182-188. https://doi.org/10.1097/WCO.0000000000001252

APA

Beschorner, N., & Nedergaard, M. (2024). Glymphatic system dysfunction in neurodegenerative diseases. Current Opinion in Neurology, 37(2), 182-188. https://doi.org/10.1097/WCO.0000000000001252

Vancouver

Beschorner N, Nedergaard M. Glymphatic system dysfunction in neurodegenerative diseases. Current Opinion in Neurology. 2024;37(2):182-188. https://doi.org/10.1097/WCO.0000000000001252

Author

Beschorner, Natalie ; Nedergaard, Maiken. / Glymphatic system dysfunction in neurodegenerative diseases. In: Current Opinion in Neurology. 2024 ; Vol. 37, No. 2. pp. 182-188.

Bibtex

@article{b80441a76e6f4c6e9c8cd21b214272f7,

title = "Glymphatic system dysfunction in neurodegenerative diseases",

abstract = "Purpose of review Purpose of this review is to update the ongoing work in the field of glymphatic and neurodegenerative research and to highlight focus areas that are particularly promising. Recent findings Multiple reports have over the past decade documented that glymphatic fluid transport is broadly suppressed in neurodegenerative diseases. Most studies have focused on Alzheimer{\textquoteright}s disease using a variety of preclinical disease models, whereas the clinical work is based on various neuroimaging approaches. It has consistently been reported that brain fluid transport is impaired in patients suffering from Alzheimer{\textquoteright}s disease compared with age-matched control subjects. Summary An open question in the field is to define the mechanistic underpinning of why glymphatic function is suppressed. Other questions include the opportunities for using glymphatic imaging for diagnostic purposes and in treatment intended to prevent or slow Alzheimer disease progression.",

keywords = "Alzheimer{\textquoteright}s disease, brain clearance, cerebral amyloid angiopathy, glymphatic system, protein aggregation",

author = "Natalie Beschorner and Maiken Nedergaard",

year = "2024",

doi = "10.1097/WCO.0000000000001252",

language = "English",

volume = "37",

pages = "182--188",

journal = "Current Opinion in Neurology",

issn = "1350-7540",

publisher = "Lippincott Williams & Wilkins, Ltd.",

number = "2",

}

RIS

TY - JOUR

T1 - Glymphatic system dysfunction in neurodegenerative diseases

AU - Beschorner, Natalie

AU - Nedergaard, Maiken

PY - 2024

Y1 - 2024

N2 - Purpose of review Purpose of this review is to update the ongoing work in the field of glymphatic and neurodegenerative research and to highlight focus areas that are particularly promising. Recent findings Multiple reports have over the past decade documented that glymphatic fluid transport is broadly suppressed in neurodegenerative diseases. Most studies have focused on Alzheimer’s disease using a variety of preclinical disease models, whereas the clinical work is based on various neuroimaging approaches. It has consistently been reported that brain fluid transport is impaired in patients suffering from Alzheimer’s disease compared with age-matched control subjects. Summary An open question in the field is to define the mechanistic underpinning of why glymphatic function is suppressed. Other questions include the opportunities for using glymphatic imaging for diagnostic purposes and in treatment intended to prevent or slow Alzheimer disease progression.

AB - Purpose of review Purpose of this review is to update the ongoing work in the field of glymphatic and neurodegenerative research and to highlight focus areas that are particularly promising. Recent findings Multiple reports have over the past decade documented that glymphatic fluid transport is broadly suppressed in neurodegenerative diseases. Most studies have focused on Alzheimer’s disease using a variety of preclinical disease models, whereas the clinical work is based on various neuroimaging approaches. It has consistently been reported that brain fluid transport is impaired in patients suffering from Alzheimer’s disease compared with age-matched control subjects. Summary An open question in the field is to define the mechanistic underpinning of why glymphatic function is suppressed. Other questions include the opportunities for using glymphatic imaging for diagnostic purposes and in treatment intended to prevent or slow Alzheimer disease progression.

KW - Alzheimer’s disease

KW - brain clearance

KW - cerebral amyloid angiopathy

KW - glymphatic system

KW - protein aggregation

U2 - 10.1097/WCO.0000000000001252

DO - 10.1097/WCO.0000000000001252

M3 - Review

C2 - 38345416

AN - SCOPUS:85187207796

VL - 37

SP - 182

EP - 188

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 2

ER -

ID: 385901487